Breyanzi Approved for Relapsed or Refractory Mantle Cell Lymphoma
The FDA has approved Breyanzi (lisocabtagene maraleucel) for the treatment of previously treated adults with relapsed or refractory mantle cell lymphoma.
Stay updated with breaking news from Transcend. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has approved Breyanzi (lisocabtagene maraleucel) for the treatment of previously treated adults with relapsed or refractory mantle cell lymphoma.
Silicon Motion Unveils Next-Generation Ultra-Fast, Single-Chip Controller for High-Density Portable SSDs, Ideally Suited for Next-Generation AI Smart Devices and Gaming Consoles
Transcend raised $40 million in a Series B funding round led by StepStone Group to enhance privacy controls in business systems. This investment will support the
Transcend raised $40 million in Series B funding to continue growing its suite of privacy and artificial intelligence governance solutions.
'Unseen' News and Views – By Baher Kamal & The Like